We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

25 hedge funds and large institutions have $5.92M invested in Benitec Biopharma in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

281% more capital invested

Capital invested by funds: $1.55M → $5.92M (+$4.36M)

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

19% more funds holding

Funds holding: 21 → 25 (+4)

2.66% more ownership

Funds ownership: 0.96% → 3.63% (+2.7%)

Holders
25
Holders Change
+4
Holders Change %
+19.05%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$7.47M
2
AC
Armistice Capital
New York
+$1.16M
3
CH
CVI Holdings
Delaware
+$963K
4
EAM
Empery Asset Management
New York
+$596K
5
ACM
Altium Capital Management
New York
+$492K

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$158K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$62K
3
Citadel Advisors
Citadel Advisors
Florida
-$58K
4
VF
Virtu Financial
New York
-$55K
5
TSS
Two Sigma Securities
New York
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
1
Franklin Resources
California
$3.72M +$7.47M +588,235 New
AC
2
Armistice Capital
New York
$578K +$1.16M +91,473 New
CH
3
CVI Holdings
Delaware
$479K +$963K +75,831 New
EAM
4
Empery Asset Management
New York
$296K +$596K +46,873 New
SCM
5
Suvretta Capital Management
New York
$286K – – –
ACM
6
Altium Capital Management
New York
$245K +$492K +38,753 New
Walleye Capital
7
Walleye Capital
New York
$71K +$143K +11,216 New
CF
8
Cantor Fitzgerald
New York
$50K +$100K +7,871 New
Renaissance Technologies
9
Renaissance Technologies
New York
$45K +$90K +7,084 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$28K -$2.69K -212 -5%
Morgan Stanley
11
Morgan Stanley
New York
$28K +$52.5K +4,129 +1,211%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$22K +$356 +28 +0.8%
Millennium Management
13
Millennium Management
New York
$19K +$20.2K +1,592 +108%
Two Sigma Investments
14
Two Sigma Investments
New York
$14K +$29K +2,285 New
UBS Group
15
UBS Group
Switzerland
$11K +$12.5K +986 +141%
State Street
16
State Street
Massachusetts
$8K – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$6K – – –
Northern Trust
18
Northern Trust
Illinois
$4K – – –
WA
19
WealthTrust Axiom
Pennsylvania
$4K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$3K +$2.92K +230 +102%
Group One Trading
21
Group One Trading
Illinois
$1K -$229 -18 -15%
Barclays
22
Barclays
United Kingdom
– -$158K -8,018 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$62K -3,170 Closed
Citadel Advisors
24
Citadel Advisors
Florida
– -$58K -2,939 Closed
VF
25
Virtu Financial
New York
– -$55K -2,788 Closed
1
2

BNTC Hedge Fund Activity: Q3 2022 in Review

25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2022, worth a combined $5.92M — up 281% from $1.55M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new BNTC positions and 6 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $7.47M. The largest seller was Barclays, exiting entirely with an estimated $158K sold.

  • 25 institutional investors held Benitec Biopharma (BNTC) as of Q3 2022, up from 21 in Q2 2022.
  • Funds reported $5.92M of Benitec Biopharma stock for Q3 2022, up 281% quarter-over-quarter.
  • 10 funds opened new Benitec Biopharma positions in Q3 2022 and 6 closed out, a net change of +4 holders.
  • The largest Benitec Biopharma buyer in Q3 2022 was Franklin Resources, an estimated $7.47M added.
  • The largest Benitec Biopharma seller in Q3 2022 was Barclays, an estimated $158K sold.

Based on aggregated 13F filings for Q3 2022.